Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lung Cancer Associated With Cystic Airspaces. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study
Overview
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
Primary outcome measures
- DFS [Time frame: From enrollment to the end of surgery for 5 years]
- OS [Time frame: From enrollment to the end of surgery for 5 years]
Secondary outcome measures (5)
- Rate of T-stage reclassification [Time frame: From enrollment to the end of surgery for 5 years]
- AI-based extraction of radiologic characteristics of cystic airspace-associated lesions [Time frame: From enrollment to the end of surgery for 5 years]
- AI to extract and analyze pathological features [Time frame: From enrollment to the end of surgery for 5 years]
- Oncogenic driver genetic alterations [Time frame: From enrollment to the end of surgery for 5 years]
- Receipt of postoperative adjuvant therapy [Time frame: From enrollment to the end of surgery for 5 years]
Eligibility criteria
Inclusion criteria
- Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
- Patients who have undergone surgical lung resection;
- Patients with complete preoperative chest CT imaging data;
- Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.
Exclusion criteria
- History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubé \[BHD\] syndrome);
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Patients with concurrent other malignancies;
- Patients with missing or poor-quality preoperative chest CT imaging data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The Second Xiangya Hospital of Central South University — Changsha
Identifiers
NCT: NCT07066813 · LYEC2025-K0017